A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE LEVELS OF BCX7353 AS AN ORAL TREATMENT FOR THE PREVENTION OF ATTACKS IN SUBJECTS WITH HEREDITARY ANGIOEDEMA
- Registry ID
- BCX7353-302
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- BIOCRYST PHARMACEUTICALS INC
- Start date
- 2019-10-23
- Last update
- 2018-01-16
Conditions
Related clinical trials
- PHASE 3 TRIAL TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF NAVENIBART IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA – ORBIT-EXPANSE
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY OF SIRNA TARGETING OF PREKALLIKREIN WITH ADX-324 IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA
- POST STUDY ACCESS OF CSL312 (GARADACIMAB) FOR THE ROUTINE PREVENTION OF
HAE ATTACKS IN PEDIATRIC PARTICIPANTS (2-11 YEARS OLD) WITH HEREDITARY
ANGIOEDEMA (HAE) WHO HAVE COMPLETED CSL312_3003 STUDY
- PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NAVENIBART IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA ¿ ALPHA-ORBIT
- A PHASE 4 OPEN-LABEL STUDY TO EVALUATE THE SAFETY AFTER SWITCHING
TO CSL312 (GARADACIMAB) FROM CURRENT PROPHYLACTIC HAE
TREATMENT IN SUBJECTS WITH HAE ¿ 12 YEARS OF AGE
- HAELO: A PHASE 3, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NTLA-2002 IN PARTICIPANTS WITH HEREDITARY ANGIOEDEMA
View on source registry